{"id":13744,"date":"2025-12-28T10:38:58","date_gmt":"2025-12-28T10:38:58","guid":{"rendered":"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744"},"modified":"2025-12-28T10:38:58","modified_gmt":"2025-12-28T10:38:58","slug":"therapeutic-drug-monitoring-of-natalizumab-to-assess-response-in-iraqi-patients-with-multiple-sclerosis-a-cross-sectional-study","status":"publish","type":"post","link":"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744","title":{"rendered":"Therapeutic Drug Monitoring of Natalizumab to Assess Response in Iraqi patients with Multiple Sclerosis: A cross sectional study"},"content":{"rendered":"

[vc_row][vc_column][vc_column_text]<\/p>\n

The College of Pharmacy discussed the MSc thesis entitled \u201cTherapeutic Drug Monitoring of Natalizumab to Assess Response in Iraqi patients with Multiple Sclerosis: A cross sectional study\u201d by the student Abbas Ahmed Kadhim and his supervisors \u00a0Lecturer Dr. Mohammed Yawuz Jamal in the Clinical Pharmacy \u00a0Department and Dr. Ali Kadhim Karem, a neurologist at Baghdad medical city.<\/span><\/p>\n

The study aimed to evaluate the clinical utility of natalizumab TDM (therapeutic drug monitoring) in Iraqi patients with relapsing remitting multiple sclerosis (RRMS) in evaluating natalizumab drug trough concentrations, anti-natalizumab antibodies (ANA) status, and their relationship with clinical outcomes.\u00a0<\/span><\/p>\n

The study included a cross-sectional analysis was conducted on 80 Iraqi patients with relapsing\u2013remitting multiple sclerosis (RRMS) who had been treated with natalizumab for at least six months in the Multiple Sclerosis Ward at Baghdad Teaching Hospital, Medical City. Clinical disability was assessed using the Expanded Disability Status Scale (EDSS), disease status (active\/inactive), and JC virus serostatus. Serum osteopontin concentrations, natalizumab trough levels, and anti-natalizumab antibodies were measured. Anti-natalizumab antibodies were quantified using a standardized quantitative ELISA method.<\/span><\/p>\n

The results showed that, the trough concentrations of natalizumab did not differ significantly between patients in remission and those with active disease (1.126 vs. 1.128\u202f\u00b5g\/mL, respectively), nor between antibody-positive and antibody-negative groups (1.130 vs. 1.119\u202f\u00b5g\/mL, respectively). Most patients exhibited concentrations close to the threshold of 1\u202f\u00b5g\/mL. \u00a0No significant correlations were observed between natalizumab trough levels and clinical variables such as EDSS or disease duration. However, smoking was significantly associated with higher trough concentrations (p\u202f=\u202f0.037).<\/span><\/p>\n

The study recommended to use serial annotation of drug levels and anti\u2011drug antibodies to link with relapse, disability progression, and discontinuation. The development of ANA in nearly one-third of patients highlights the ongoing relevance of immunogenicity and the need for vigilant monitoring. \u00a0Expanded PK\/PD profiling across subgroups (disease duration, body weight, smoking, comorbidities) is needed.<\/span><\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column]

<\/div>
\"\"
<\/i><\/div><\/a><\/div><\/div>
\"\"
<\/i><\/div><\/a><\/div><\/div>
\"\"
<\/i><\/div><\/a><\/div><\/div><\/div><\/div>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column][vc_column_text] The College of Pharmacy discussed the MSc thesis entitled \u201cTherapeutic Drug Monitoring of Natalizumab to Assess Response in Iraqi … <\/i>more<\/span><\/a><\/p>\n","protected":false},"author":9,"featured_media":13746,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[3,7],"tags":[],"class_list":["post-13744","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news","category-dissuasion"],"yoast_head":"\nTherapeutic Drug Monitoring of Natalizumab to Assess Response in Iraqi patients with Multiple Sclerosis: A cross sectional study - College of Pharmacy<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Therapeutic Drug Monitoring of Natalizumab to Assess Response in Iraqi patients with Multiple Sclerosis: A cross sectional study - College of Pharmacy\" \/>\n<meta property=\"og:description\" content=\"[vc_row][vc_column][vc_column_text] The College of Pharmacy discussed the MSc thesis entitled \u201cTherapeutic Drug Monitoring of Natalizumab to Assess Response in Iraqi ... more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744\" \/>\n<meta property=\"og:site_name\" content=\"College of Pharmacy\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/collegeofpharmacy1\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-28T10:38:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/en.copharm.uobaghdad.edu.iq\/wp-content\/uploads\/sites\/80\/2025\/12\/Picture1-13.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"624\" \/>\n\t<meta property=\"og:image:height\" content=\"468\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"copharm\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"copharm\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744#article\",\"isPartOf\":{\"@id\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744\"},\"author\":{\"name\":\"copharm\",\"@id\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/#\/schema\/person\/85a43e42ae13b942c002c21c7772fd83\"},\"headline\":\"Therapeutic Drug Monitoring of Natalizumab to Assess Response in Iraqi patients with Multiple Sclerosis: A cross sectional study\",\"datePublished\":\"2025-12-28T10:38:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744\"},\"wordCount\":357,\"publisher\":{\"@id\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/#organization\"},\"image\":{\"@id\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744#primaryimage\"},\"thumbnailUrl\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/wp-content\/uploads\/sites\/80\/2025\/12\/Picture1-13.jpg\",\"articleSection\":[\"Activates\",\"dissuasion\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744\",\"url\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744\",\"name\":\"Therapeutic Drug Monitoring of Natalizumab to Assess Response in Iraqi patients with Multiple Sclerosis: A cross sectional study - College of Pharmacy\",\"isPartOf\":{\"@id\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744#primaryimage\"},\"image\":{\"@id\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744#primaryimage\"},\"thumbnailUrl\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/wp-content\/uploads\/sites\/80\/2025\/12\/Picture1-13.jpg\",\"datePublished\":\"2025-12-28T10:38:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744#primaryimage\",\"url\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/wp-content\/uploads\/sites\/80\/2025\/12\/Picture1-13.jpg\",\"contentUrl\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/wp-content\/uploads\/sites\/80\/2025\/12\/Picture1-13.jpg\",\"width\":624,\"height\":468},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Therapeutic Drug Monitoring of Natalizumab to Assess Response in Iraqi patients with Multiple Sclerosis: A cross sectional study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/#website\",\"url\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/\",\"name\":\"College of Pharmacy\",\"description\":\"University of baghdad\",\"publisher\":{\"@id\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/#organization\",\"name\":\"University of Baghdad\",\"url\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/wp-content\/uploads\/sites\/80\/2024\/05\/pharmacy-logo.png\",\"contentUrl\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/wp-content\/uploads\/sites\/80\/2024\/05\/pharmacy-logo.png\",\"width\":200,\"height\":188,\"caption\":\"University of Baghdad\"},\"image\":{\"@id\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/collegeofpharmacy1\",\"https:\/\/www.instagram.com\/college_of_pharmacy_uob\/?igsh=NWcwMnFpd2M5bDdt\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/#\/schema\/person\/85a43e42ae13b942c002c21c7772fd83\",\"name\":\"copharm\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f92b31e3166ccc8eb8809e0d2fd33dc624d190730b3e36686c99ffdac172690b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f92b31e3166ccc8eb8809e0d2fd33dc624d190730b3e36686c99ffdac172690b?s=96&d=mm&r=g\",\"caption\":\"copharm\"},\"url\":\"https:\/\/en.copharm.uobaghdad.edu.iq\/?author=9\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Therapeutic Drug Monitoring of Natalizumab to Assess Response in Iraqi patients with Multiple Sclerosis: A cross sectional study - College of Pharmacy","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744","og_locale":"en_US","og_type":"article","og_title":"Therapeutic Drug Monitoring of Natalizumab to Assess Response in Iraqi patients with Multiple Sclerosis: A cross sectional study - College of Pharmacy","og_description":"[vc_row][vc_column][vc_column_text] The College of Pharmacy discussed the MSc thesis entitled \u201cTherapeutic Drug Monitoring of Natalizumab to Assess Response in Iraqi ... more","og_url":"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744","og_site_name":"College of Pharmacy","article_publisher":"https:\/\/www.facebook.com\/collegeofpharmacy1","article_published_time":"2025-12-28T10:38:58+00:00","og_image":[{"width":624,"height":468,"url":"https:\/\/en.copharm.uobaghdad.edu.iq\/wp-content\/uploads\/sites\/80\/2025\/12\/Picture1-13.jpg","type":"image\/jpeg"}],"author":"copharm","twitter_card":"summary_large_image","twitter_misc":{"Written by":"copharm","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744#article","isPartOf":{"@id":"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744"},"author":{"name":"copharm","@id":"https:\/\/en.copharm.uobaghdad.edu.iq\/#\/schema\/person\/85a43e42ae13b942c002c21c7772fd83"},"headline":"Therapeutic Drug Monitoring of Natalizumab to Assess Response in Iraqi patients with Multiple Sclerosis: A cross sectional study","datePublished":"2025-12-28T10:38:58+00:00","mainEntityOfPage":{"@id":"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744"},"wordCount":357,"publisher":{"@id":"https:\/\/en.copharm.uobaghdad.edu.iq\/#organization"},"image":{"@id":"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744#primaryimage"},"thumbnailUrl":"https:\/\/en.copharm.uobaghdad.edu.iq\/wp-content\/uploads\/sites\/80\/2025\/12\/Picture1-13.jpg","articleSection":["Activates","dissuasion"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744","url":"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744","name":"Therapeutic Drug Monitoring of Natalizumab to Assess Response in Iraqi patients with Multiple Sclerosis: A cross sectional study - College of Pharmacy","isPartOf":{"@id":"https:\/\/en.copharm.uobaghdad.edu.iq\/#website"},"primaryImageOfPage":{"@id":"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744#primaryimage"},"image":{"@id":"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744#primaryimage"},"thumbnailUrl":"https:\/\/en.copharm.uobaghdad.edu.iq\/wp-content\/uploads\/sites\/80\/2025\/12\/Picture1-13.jpg","datePublished":"2025-12-28T10:38:58+00:00","breadcrumb":{"@id":"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744#primaryimage","url":"https:\/\/en.copharm.uobaghdad.edu.iq\/wp-content\/uploads\/sites\/80\/2025\/12\/Picture1-13.jpg","contentUrl":"https:\/\/en.copharm.uobaghdad.edu.iq\/wp-content\/uploads\/sites\/80\/2025\/12\/Picture1-13.jpg","width":624,"height":468},{"@type":"BreadcrumbList","@id":"https:\/\/en.copharm.uobaghdad.edu.iq\/?p=13744#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/en.copharm.uobaghdad.edu.iq\/"},{"@type":"ListItem","position":2,"name":"Therapeutic Drug Monitoring of Natalizumab to Assess Response in Iraqi patients with Multiple Sclerosis: A cross sectional study"}]},{"@type":"WebSite","@id":"https:\/\/en.copharm.uobaghdad.edu.iq\/#website","url":"https:\/\/en.copharm.uobaghdad.edu.iq\/","name":"College of Pharmacy","description":"University of baghdad","publisher":{"@id":"https:\/\/en.copharm.uobaghdad.edu.iq\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/en.copharm.uobaghdad.edu.iq\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/en.copharm.uobaghdad.edu.iq\/#organization","name":"University of Baghdad","url":"https:\/\/en.copharm.uobaghdad.edu.iq\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/en.copharm.uobaghdad.edu.iq\/#\/schema\/logo\/image\/","url":"https:\/\/en.copharm.uobaghdad.edu.iq\/wp-content\/uploads\/sites\/80\/2024\/05\/pharmacy-logo.png","contentUrl":"https:\/\/en.copharm.uobaghdad.edu.iq\/wp-content\/uploads\/sites\/80\/2024\/05\/pharmacy-logo.png","width":200,"height":188,"caption":"University of Baghdad"},"image":{"@id":"https:\/\/en.copharm.uobaghdad.edu.iq\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/collegeofpharmacy1","https:\/\/www.instagram.com\/college_of_pharmacy_uob\/?igsh=NWcwMnFpd2M5bDdt"]},{"@type":"Person","@id":"https:\/\/en.copharm.uobaghdad.edu.iq\/#\/schema\/person\/85a43e42ae13b942c002c21c7772fd83","name":"copharm","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/en.copharm.uobaghdad.edu.iq\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f92b31e3166ccc8eb8809e0d2fd33dc624d190730b3e36686c99ffdac172690b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f92b31e3166ccc8eb8809e0d2fd33dc624d190730b3e36686c99ffdac172690b?s=96&d=mm&r=g","caption":"copharm"},"url":"https:\/\/en.copharm.uobaghdad.edu.iq\/?author=9"}]}},"modified_by":"copharm","_links":{"self":[{"href":"https:\/\/en.copharm.uobaghdad.edu.iq\/index.php?rest_route=\/wp\/v2\/posts\/13744","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/en.copharm.uobaghdad.edu.iq\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/en.copharm.uobaghdad.edu.iq\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/en.copharm.uobaghdad.edu.iq\/index.php?rest_route=\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/en.copharm.uobaghdad.edu.iq\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13744"}],"version-history":[{"count":1,"href":"https:\/\/en.copharm.uobaghdad.edu.iq\/index.php?rest_route=\/wp\/v2\/posts\/13744\/revisions"}],"predecessor-version":[{"id":13749,"href":"https:\/\/en.copharm.uobaghdad.edu.iq\/index.php?rest_route=\/wp\/v2\/posts\/13744\/revisions\/13749"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/en.copharm.uobaghdad.edu.iq\/index.php?rest_route=\/wp\/v2\/media\/13746"}],"wp:attachment":[{"href":"https:\/\/en.copharm.uobaghdad.edu.iq\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13744"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/en.copharm.uobaghdad.edu.iq\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13744"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/en.copharm.uobaghdad.edu.iq\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13744"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}